VAX125

BIOLOGICAL2 trials

Sponsors

VaxInnate Corporation

Conditions

Influenza

Phase 1

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

CompletedNCT00730457

VaxInnate CorporationInfluenza

Start: 2008-07-31End: 2009-06-30Updated: 2014-09-23

Phase 2

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

CompletedNCT00966238

VaxInnate CorporationInfluenza

Start: 2009-09-30End: 2011-03-31Updated: 2014-10-02